AFL Stock Analysis — Aflac Incorporated
Sector: Financials
AI Verdict
Aflac trades at 15.2x next year's earnings while analysts expect -15.2% EPS contraction, so you're paying a premium the numbers don't yet support unless its sticky distribution moat delivers a surprise turnaround.
Competitive Moat
Aflac dominates the supplemental health and life insurance market in Japan and the U.S. through long-standing distribution partnerships with employers and banks, creating sticky customer relationships that are hard for new entrants to disrupt. Its scale and brand recognition in cancer and medical insurance products give it pricing power and persistent renewal rates.
Summary
Aflac stands out for its entrenched position in Japanese supplemental insurance, but faces shrinking earnings expectations.
Where It Stands
Aflac returned 6.87% over the past year, trades at 15.2x forward earnings versus the financial sector's 14x median, and its RSI of 46.0 signals the stock is cooling off rather than overbought.
Key Metrics
- RSI: 46 — Neutral
- Trailing P/E: 12.9x
- Forward P/E: 15.2x
- Earnings Growth: -0.2%
- Revenue Growth: -0.1%
- Market Cap: $58.0B
- Dividend Yield: 0.02%
- 1-Year Return: 6.87%
- 52-Week High: $119.32
- 52-Week Low: $96.95
Analyst Consensus
3 Buy · 12 Hold · 8 Sell (23 analysts)
Bull Case
With a trailing P/E of 12.9x, Aflac is priced below its own forward multiple, suggesting the market still sees value in its $58.0B scale and established customer base.
Bear Case
Forward EPS is expected to drop by -15.2%, so if the P/E reverts to the sector median of 14x, the stock could see further downside from multiple compression.
Catalyst to Watch
Watch for the next quarterly earnings — any sign of stabilizing or rebounding EPS could challenge the current negative growth narrative.